Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily F Higgs

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Cancer Immunology Research|June 13, 2025
Tumor cell-intrinsic Decr2 regulates ferroptosis and immunotherapy efficacyShuyin Li, Jason W Shapiro, Hardik Shah, et al.
Medrxiv : the Preprint Server for Health Sciences|August 4, 2020
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Clinical Pharmacology and Therapeutics|November 19, 2020
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 PneumoniaGarth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Research Square|November 30, 2021
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunctionSherin J Rouhani, Jonathan A Trujillo, Athalia R Pyzer, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Cancer Immunology Research|June 13, 2025
Tumor cell-intrinsic Decr2 regulates ferroptosis and immunotherapy efficacyShuyin Li, Jason W Shapiro, Hardik Shah, et al.
Medrxiv : the Preprint Server for Health Sciences|August 4, 2020
COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19Garth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Clinical Pharmacology and Therapeutics|November 19, 2020
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 PneumoniaGarth W Strohbehn, Brian L Heiss, Sherin J Rouhani, et al.
Research Square|November 30, 2021
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunctionSherin J Rouhani, Jonathan A Trujillo, Athalia R Pyzer, et al.
Pageof 2